查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2094669

不孕症治療市場－2026-2032年全球市場預測

Infertility Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，不孕症治療市場將成長至 143 億美元，複合年成長率為 11.71%。

主要市場統計數據
基準年 2025 65.8億美元
預計年份：2026年 73.2億美元
預測年份 2032 143億美元
複合年成長率 (%) 11.71%

不孕症治療執行摘要

隨著人們對延遲生育、生活方式相關不孕症、多囊性卵巢症候群、子宮卵巢異位症、男性因素不孕症以及輔助生殖技術的認知不斷提高，不孕症治療正從一項小眾專科服務轉變為生殖醫學的核心領域，並重塑著患者的需求。臨床上，該領域涵蓋不孕症診斷檢測、促進排卵、子宮腔內人工授精、體外受精、卵胞漿內單一精子注射、供精、生育力保存、胚胎胚胎著床前遺傳學檢測和冷凍保存。世界衛生組織（WHO）將不孕症認定為生殖系統疾病，並估計大約六分之一的成年人在一生中的某個階段會經歷不孕不育。這凸顯了不孕症治療的巨大未滿足需求，無論收入水平或居住地如何。如今最具競爭力的不孕症治療策略強調實證方案、病人安全、檢查室品質、胚胎選擇、經濟承受能力、合規性和持續性照護。隨著生殖醫學變得越來越個人化，醫療保健提供者正擴大將醫學專業知識與數位互動、倫理諮詢和綜合生育護理途徑相結合。

不孕症治療領域的變革性變化

隨著患者要求更早診斷、更透明的治療結果報告以及一體化的醫療服務，不孕症治療格局正在經歷結構性轉變。對於那些延遲生育、接受生殖毒性癌症治療以及尋求選擇性卵子和精子冷凍的人來說，保留生育功能變得越來越重要。同時，男性不孕症也日益受到臨床關注，這得益於精液分析、泌尿系統評估、生活方式改善以及先進的精子選擇技術的進步。檢查室創新仍然是一項關鍵變革，玻璃化冷凍、延時胚胎監測、改良的培養基和增強的冷凍保存技術有助於提高輔助生殖技術結果的穩定性。監管要求也日益嚴格，尤其是在胚胎處理、捐贈者篩檢、基因檢測、資料保護、知情同意、廣告宣傳和跨境生殖醫學方面。然而，醫療資源的取得仍存在不平等。公共醫療報銷、保險覆蓋範圍要求、文化接受度、專科醫生密度和法律體制因地區而異，這些因素都會影響患者獲得不孕症診斷和治療的過程。這些變化正促使診所、醫院、診斷服務提供者和政策制定者朝著以患者為中心、結果監測和符合倫理的生殖醫學模式發展。

人工智慧對不孕症治療的累積影響

人工智慧 (AI) 透過輔助胚胎評估、工作流程優先順序、卵巢刺激監測、影像診斷和患者溝通，對生育治療的影響日益顯著。在胚胎學實驗室中，AI 驅動的影像分析，特別是與延時成像相結合，正受到高度重視，以提高胚胎分級的一致性並減少觀察者間的差異。在臨床決策支援方面，機器學習模型有助於識別荷爾蒙水平、年齡、卵巢儲備指標、精液參數、超音波觀察和先前治療週期結果等方面的模式，但這些工具需要經過仔細檢驗和臨床醫生的監督。 AI 在預約分診、用藥提醒、病患教育和電子健康記錄審查方面也具有實際應用價值，有助於減輕高病患量生育中心的行政負擔。然而，AI 的累積效應取決於演算法的透明度、多樣化的訓練資料集、隱私保護、可解釋性以及對醫療設備和健康資料相關法規的遵守情況。由於生育治療的結果受生物學、臨床、行為學和檢查室變數的影響，人工智慧不應被視為取代生殖內分泌學家、胚胎學家、遺傳諮詢師和生育護士，而應被視為一種補充他們能力的輔助技術。為了最有效地應用人工智慧，至關重要的是將經過檢驗的人工智慧工具與品管系統、知情同意、可審計性和公平獲取途徑相結合。

關於不孕症治療的關鍵區域見解

亞太地區是輔助生殖治療領域最具活力的地區之一，其發展受多種因素影響，例如龐大的育齡人口、都市區晚婚晚育、醫療旅遊的興起，以及中國、印度、日本、韓國、澳大利亞和東南亞等地私立生育診所網路的擴張。各地區的監管體系差異顯著，有些地區提供廣泛的輔助生殖技術服務，而有些地區則對捐精、代孕、胚胎檢測和胚胎保存等事項實施嚴格的規定。北美地區擁有先進的臨床基礎設施、較高的體外受精、生育力保存和基因檢測普及率，並與數位醫療緊密結合，但能否獲得治療取決於各州和地區的保險覆蓋範圍、雇主提供的生育福利、專科醫生的分佈以及個人的經濟能力。在歐洲，輔助生殖技術的成熟管治透過國家登記系統、組織和細胞安全要求、品質標準以及部分國家的公共或部分報銷得以維持，但在捐贈者匿名、胚胎冷凍、代孕和胚胎著床前遺傳學檢測等方面仍存在法律差異。在拉丁美洲，由於專科醫生資源的改善和跨境治療興趣的日益成長，對生育服務的需求不斷增加，但保險報銷差異和收入不平等仍然是獲得服務的障礙。在非洲，由於專科醫生短缺、自付費用高昂、感染疾病導致的不孕症負擔以及先進生殖技術普及程度不平衡，生育需求在很大程度上仍未得到滿足，儘管主要都市區的診斷和體外受精（IVF）能力正在逐步提高。在中東，人們對家庭組成護理的認知程度很高，對專業診所的投入也很大，宗教和倫理框架會影響允許的程序（特別是捐精的使用、婚姻要求、胚胎處置和冷凍保存做法）。

主要經濟和政策板塊的主要群體分析

北約成員國與北美和歐洲的先進生育體系高度重合，這些國家的生殖醫學服務受到監管、跨境醫療使用趨勢、資料安全要求、軍人家庭的健康需求以及各國輔助生殖技術政策差異的影響。七國集團（G7）國家通常具有較高的臨床能力、較高的檢查室標準、活躍的研究以及對保護生殖功能的日益重視，但各成員國承擔治療費用和保險報銷的能力差異很大。金磚國家整體呈現不同的生育趨勢。中國和印度擁有龐大的患者群體和不斷擴展的生育基礎設施，巴西擁有成熟的生育社群，俄羅斯歷來支持輔助生殖技術（ART）的廣泛應用，而南非是非洲生育領域的重要中心。歐盟透過國家醫療保健體系、登記制度、組織和細胞安全要求以及資料保護法規，為輔助生殖技術提供了一個相對系統化的環境。然而，各國在治療資格、公共資金、捐贈者政策以及基因檢測授權等方面仍有差異。在東南亞國協，都市化、生育年齡延遲以及對私人醫療保健的投入推動了體外受精（IVF）、不孕症診斷和冷凍保存的需求，進一步提升了生育治療的重要性。前往監管和費用較為優惠地區的醫療旅遊也促進了病患湧入。海灣合作理事會（GCC）國家的特點是積極投資醫療保健領域，不斷擴大生育診所的規模，並擁有獨特的文化背景，其生殖健康管治尤其注重婚姻狀況、血統、胚胎處理、宗教規範以及某些司法管轄區對第三方生育的限制。

主要國家不孕症治療趨勢

美國擁有高度發展的生育醫療體系，體外受精（IVF）、生殖細胞保存、捐卵/捐精服務和基因檢測等技術應用廣泛；然而，能否獲得治療很大程度上取決於保險覆蓋範圍、雇主福利、地理位置以及自付費用。中國正積極應對人口壓力和政策變化，擴大生殖醫學服務能力，但監管仍影響輔助生殖技術（ART）、胚胎檢測和診所資格的取得。德國和法國擁有成熟的生育醫療體系，具備清晰的法律體制和報銷機制、全國統一的品質標準以及對胚胎相關操作的嚴格管治。義大利和西班牙則展現出高超的臨床技術，尤其是西班牙，憑藉其完善的法律和臨床環境，在捐卵/捐精治療方面表現突出。日本由於生育年齡延遲和人口老化，面臨日益成長的生育治療需求，並得到了政策的重視和治療經費的增加。加拿大提供高品質的生殖醫療服務，但公共資金投入和診所數量因省份而異。同時，印度憑藉大規模的私人生育生態系統和更規範的輔助生殖技術法規結構，正取得進展。巴西擁有完善的輔助生殖技術產業和成熟的專業技術，這得益於推遲生育的需求以及都市區醫療保健服務的擴展。英國的生育監管框架非常嚴格，其特點是國家監管、診所高度透明的報告製度以及透過區域委託系統提供的多樣化公共資金。另一方面，由於私人診所的成長和跨境患者的需求，墨西哥已成為拉丁美洲重要的生育目的地。澳洲擁有成熟的輔助生殖技術（ART）產業，其健全的通報系統基於註冊制度，並由公共報銷體系支持病患就診。韓國正加強對生育的支持，以應對其極低的出生率，政策措施和先進的醫療保健基礎設施促進了治療的可及性。俄羅斯的輔助生殖技術服務普及，但地緣政治、法律和支付條件可能會影響國際患者的流動。在這些國家，獲得生育治療的機會受到年齡限制、公共或私人資金、捐贈者規定、診所密度、檢查室品質標準以及社會對輔助生殖技術的接受程度的影響。

為不孕症治療領域的領導者提供的實用建議

行業領導者應優先考慮以實證醫學為基礎的生育治療模式，在不誇大臨床療效的前提下，提高治療的可及性、安全性和患者體驗。醫療機構應投資於標準化的檢查室品管系統、透明的治療結果報告、生殖內分泌學和胚胎學方面的專業知識，以及包括泌尿系統、遺傳學、心理健康、營養和諮詢在內的多學科診療服務。應利用數位化平台簡化病患入院流程、週期監測、藥物遵從性和教育，同時保護敏感的生殖健康資料。實施人工智慧的機構必須檢驗工具的臨床有效性，監測偏差，記錄決策過程，並在胚胎評估和治療計畫中保持人工監督。在進行地理擴張時，應考慮當地的法規、文化規範、報銷機制和專家資源，尤其是在捐贈生殖細胞、代孕、胚胎檢測和胚胎儲存受到嚴格監管的地區。領導者還需要透過資金籌措模式、雇主合作、公私合營以及簡化診療流程來解決成本效益問題。長期競爭力取決於透過合乎道德的行銷、清晰的知情同意實踐、以患者為中心的溝通、健全的冷凍保存管治以及對臨床品質指標的持續測量來建立信任。

調查方法

本執行摘要基於系統的二手研究途徑，重點關注檢驗的公共衛生、臨床、監管和人口統計資訊來源。該調查方法整合了世界衛生組織、國家生育登記處、同行評審的生殖醫學文獻、臨床學會指南、政府政策文件、保險和報銷信息，以及公開的輔助生殖技術、配子捐贈、胚胎保存、基因檢測和生育力保存法規結構的證據。透過檢驗醫療保健基礎設施、生育治療的可近性、報銷政策、人口趨勢、法律認可度、臨床能力以及生殖技術的採用情況，整合了區域和國家層面的具體見解。本分析不涉及市場規模計算、市場佔有率估算或預測；而是著重於對生育趨勢進行數據驅動的定性解讀。儘管研究結果已通過多個可靠資訊來源進行交叉檢驗，以減少偏差並確保一致性，但我們也認知到，不同司法管轄區關於輔助生殖技術（ART）的法規和政策存在顯著差異。

結論

隨著全球不孕症負擔與人口結構變化、晚育以及生育選擇日益增多交織在一起，生育治療正成為一個更加一體化、技術驅動且受政策影響的醫療保健領域。體外受精（IVF）、冷凍保存、基因檢測、生育力保存和數位醫療的進步正在改善治療路徑，而人工智慧（AI）若能得到負責任的應用，則有望提高治療的一致性和效率。報銷制度、監管、文化和臨床基礎設施的區域和國家差異，持續影響患者獲得治療的機會和決策。最具韌性的相關人員將是那些將卓越的臨床水平與合乎倫理的管治、對成本效益的承諾、透明的溝通以及以患者為中心的護理相結合的機構。隨著對生殖醫學需求的成長，生育治療的未來不僅將由技術進步塑造，還將由公平的醫療機會、對監管的信任以及患者療效的可衡量改善所決定。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 不孕症治療市場：依治療類型分類

  • 藥物治療
    • 誘導排卵
    • 黃體期支持
  • 輔助生殖技術
    • 體外受精
    • 胞漿內單一精子注射
  • 人工授精
    • 子宮內人工授精
    • 子宮頸內人工授精
  • 手術治療
    • 腹腔鏡手術
    • 子子宮鏡手術

第8章：不孕症治療市場：依產品類型分類

  • 裝置
    • 冷凍保存系統
    • 影像系統
    • 培養箱
    • 雷射系統
    • 微型機械手臂系統
    • 卵子抽吸泵
    • 精子分析系統
    • 精子分離裝置
    • 胚胎監測/現場服務
    • 男性生殖醫學檢測設備
  • 媒體
    • 冷凍保存培養基
    • 培養基
  • 配件和耗材

第9章：不孕症治療市場：依診斷分類

  • 女性不孕症
    • 造影（HSG）
    • 排卵測試
  • 男性不孕
    • 驗血
    • 精液分析
    • 睪丸切片檢查

第10章：不孕症治療市場：依不孕症類型分類

  • 原發性不孕症
  • 續發性不孕症

第11章：不孕症治療市場：依最終用戶分類

  • 不孕症治療診所
  • 醫院
  • 門診手術中心
  • 冷凍庫

第12章 不孕症治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 歐洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：不孕症治療市場：依群體分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 不孕症治療市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 加拿大
  • 印度
  • 巴西
  • 英國
  • 墨西哥
  • 法國
  • 澳洲
  • 義大利
  • 韓國
  • 俄羅斯
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Merck KGaA
  • Ferring International Center SA
  • IVIRMA
  • CooperSurgical, Inc.
  • Vitrolife Sweden AB
  • FUJIFILM Biosciences
  • Monash IVF
  • Genea Group
  • Cryoport Systems, LLC.
  • Bayer AG
  • Abbott Laboratories
  • Hamilton Thorne Ltd.
  • TMRW Life Sciences, Inc.
  • Embryolab
  • Cook Medical LLC
  • AbbVie Inc.
  • Esco Micro Pte. Ltd.
  • Fairhaven Health, Inc.
  • NOW-fertility SA
  • ReproTech LLC
  • Seegene, Inc.
  • Thermo Fisher Scientific, Inc.
  • Xytex Corporation
  • Zuellig Pharma Group
  • Zydus Group
Product Code: MRR-3E32260F8122

The Infertility Treatment Market is projected to grow by USD 14.30 billion at a CAGR of 11.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.58 billion
Estimated Year [2026] USD 7.32 billion
Forecast Year [2032] USD 14.30 billion
CAGR (%) 11.71%

Infertility Treatment Executive Summary

Infertility treatment is moving from a niche specialist service to a core component of reproductive healthcare as delayed parenthood, lifestyle-related fertility challenges, polycystic ovary syndrome, endometriosis, male-factor infertility, and rising awareness of assisted reproductive technology reshape patient demand. Clinically, the field spans diagnostic fertility testing, ovulation induction, intrauterine insemination, in vitro fertilization, intracytoplasmic sperm injection, donor gametes, fertility preservation, preimplantation genetic testing, and cryopreservation. The World Health Organization recognizes infertility as a disease of the reproductive system and estimates that roughly one in six adults experience infertility during their lifetime, underscoring the scale of unmet need across income groups and geographies. The most competitive infertility treatment strategies now emphasize evidence-based protocols, patient safety, laboratory quality, embryo selection, affordability, regulatory compliance, and continuity of care. As reproductive medicine becomes more personalized, providers are increasingly aligning medical expertise with digital engagement, ethical counseling, and integrated fertility care pathways.

Transformative Shifts in the Infertility Treatment Landscape

The infertility treatment landscape is undergoing structural change as patients seek earlier diagnosis, more transparent success communication, and less fragmented care. Fertility preservation is gaining relevance among individuals delaying family formation, patients undergoing gonadotoxic cancer therapies, and people pursuing elective egg or sperm freezing. At the same time, male infertility is receiving greater clinical attention, supported by semen analysis improvements, urological evaluation, lifestyle interventions, and advanced sperm selection techniques. Laboratory innovation remains a defining shift, with vitrification, time-lapse embryo monitoring, refined culture media, and improved cryostorage practices supporting more consistent assisted reproductive technology outcomes. Regulatory expectations are also becoming more rigorous, particularly around embryo handling, donor screening, genetic testing, data protection, consent, advertising claims, and cross-border reproductive care. Access remains uneven: public reimbursement, insurance mandates, cultural acceptance, specialist density, and legal frameworks differ widely, influencing how patients move through infertility diagnosis and treatment. These shifts are pushing clinics, hospitals, diagnostics providers, and policymakers toward patient-centered, outcome-monitored, and ethically governed reproductive healthcare models.

Cumulative Impact of Artificial Intelligence on Fertility Care

Artificial intelligence is increasingly influencing infertility treatment by supporting embryo assessment, workflow prioritization, ovarian stimulation monitoring, image interpretation, and patient communication. In embryology laboratories, AI-enabled image analysis is being evaluated to improve consistency in embryo grading and reduce inter-observer variability, particularly when combined with time-lapse imaging. In clinical decision support, machine learning models can help identify patterns across hormone levels, age, ovarian reserve markers, semen parameters, ultrasound findings, and prior cycle outcomes, although such tools require careful validation and clinician oversight. AI also has operational value in appointment triage, medication reminders, patient education, and electronic record review, helping reduce administrative burden in high-volume fertility centers. However, the cumulative impact of AI depends on transparent algorithms, diverse training datasets, privacy safeguards, explainability, and compliance with medical device and health data regulations. Because fertility outcomes are affected by biological, clinical, behavioral, and laboratory variables, AI should be viewed as an augmenting technology rather than a replacement for reproductive endocrinologists, embryologists, genetic counselors, and fertility nurses. The strongest adoption pathways will combine validated AI tools with quality management systems, informed consent, auditability, and equitable access.

Key Regional Insights for Infertility Treatment

Asia-Pacific is one of the most dynamic regions for infertility treatment, shaped by large reproductive-age populations, delayed marriage and childbirth in urban centers, rising medical travel, and expanding private fertility clinic networks in China, India, Japan, South Korea, Australia, and Southeast Asia. Regulatory approaches vary significantly, with some jurisdictions permitting broad assisted reproductive technology services and others applying strict rules to donor gametes, surrogacy, embryo testing, and storage. North America is characterized by advanced clinical infrastructure, high adoption of in vitro fertilization, fertility preservation, genetic testing, and strong digital health integration, while access is influenced by state or provincial insurance coverage, employer fertility benefits, specialist distribution, and out-of-pocket affordability. Europe maintains mature assisted reproductive technology governance through national registries, tissue and cell safety requirements, quality standards, and public or partial reimbursement in several countries, but legal differences persist around donor anonymity, embryo freezing, surrogacy, and preimplantation genetic testing. Latin America shows growing demand for fertility services, supported by improving specialist availability and cross-border treatment interest, although reimbursement gaps and income inequality affect access. Africa faces substantial unmet infertility care needs due to limited specialist capacity, high out-of-pocket costs, infection-related infertility burdens, and uneven availability of advanced reproductive technology, yet major urban centers are gradually expanding diagnostic and IVF capabilities. The Middle East is shaped by high awareness of family-building care, investment in specialist clinics, and religious and ethical frameworks that influence permitted procedures, particularly donor use, marital eligibility, embryo disposition, and cryostorage practices.

Key Group Insights Across Major Economic and Policy Blocs

NATO countries overlap substantially with developed fertility care systems in North America and Europe, where reproductive healthcare delivery is influenced by regulatory scrutiny, cross-border care patterns, data security requirements, military family health needs, and differing national policies on assisted reproduction. G7 countries generally have advanced clinical capabilities, high laboratory standards, robust research activity, and growing focus on fertility preservation, but affordability and reimbursement vary markedly across members. BRICS economies collectively represent diverse infertility treatment dynamics: China and India have large patient populations and expanding fertility infrastructure, Brazil has an established reproductive medicine community, Russia has historically supported broad ART availability, and South Africa serves as a key hub within the African fertility landscape. The European Union provides a comparatively structured environment for assisted reproductive technology through national health systems, registries, tissue and cell safety requirements, and data protection rules, although treatment eligibility, public funding, donor policies, and genetic testing permissions remain country-specific. ASEAN countries are increasingly important in infertility treatment as urbanization, later childbearing, and private healthcare investment support demand for IVF, fertility diagnostics, and cryopreservation, with medical travel contributing to patient flows where regulatory and cost conditions are favorable. The GCC is distinguished by strong healthcare investment, rising fertility clinic capacity, and culturally specific reproductive medicine governance that places particular emphasis on marital status, lineage, embryo handling, religious compliance, and limits on third-party reproduction in several jurisdictions.

Key Country Insights in Infertility Treatment

The United States has a highly advanced infertility treatment environment with strong uptake of IVF, fertility preservation, donor services, and genetic testing, although access is strongly shaped by insurance mandates, employer benefits, geography, and out-of-pocket costs. China is expanding reproductive medicine capacity in response to demographic pressures and policy changes, while regulatory oversight continues to shape ART availability, embryo testing, and clinic licensing. Germany and France maintain mature fertility care systems with defined legal and reimbursement structures, national quality expectations, and careful governance of embryo-related practices, while Italy and Spain show strong clinical expertise; Spain is particularly prominent in donor-related treatment due to its legal and clinical environment. Japan faces fertility demand linked to delayed childbirth and demographic aging, supported by policy attention and expanded financial support for treatment. Canada combines high-quality reproductive care with provincial variation in public funding and clinic availability, while India is advancing through a large private fertility ecosystem and a more formalized assisted reproductive technology regulatory framework. Brazil has a well-developed assisted reproduction sector and established specialist expertise, supported by demand from delayed parenthood and urban healthcare expansion. The United Kingdom operates under a highly regulated fertility framework with national oversight, transparent clinic reporting, and variable public funding across local commissioning systems, while Mexico is an important Latin American fertility destination due to private clinic growth and cross-border patient interest. Australia has a well-established ART sector with strong registry-based reporting and patient access supported by public reimbursement mechanisms. South Korea is strengthening fertility support in response to very low birth rates, with policy measures and advanced healthcare infrastructure encouraging treatment access. Russia has had broad ART service availability, though geopolitical, legal, and payment conditions can affect international patient flows. Across these countries, infertility treatment access is shaped by age eligibility, public or private funding, donor rules, clinic density, laboratory quality standards, and public acceptance of assisted reproductive technology.

Actionable Recommendations for Infertility Treatment Leaders

Industry leaders should prioritize evidence-based fertility care models that improve access, safety, and patient experience without overstating clinical outcomes. Providers should invest in standardized laboratory quality systems, transparent outcome reporting, reproductive endocrinology expertise, embryology training, and multidisciplinary care that includes urology, genetics, mental health, nutrition, and counseling. Digital platforms should be used to streamline patient onboarding, cycle monitoring, medication adherence, and education while protecting sensitive reproductive health data. Organizations adopting AI should validate tools clinically, monitor bias, document decision pathways, and maintain human oversight in embryo assessment and treatment planning. Geographic expansion should be guided by local regulation, cultural norms, reimbursement structures, and specialist availability, particularly in regions where donor gametes, surrogacy, embryo testing, and storage are tightly governed. Leaders should also address affordability through financing models, employer partnerships, public-private collaboration, and simplified care pathways. Long-term competitiveness will depend on building trust through ethical marketing, clear consent practices, patient-centered communication, strong cryostorage governance, and continuous measurement of clinical quality indicators.

Research Methodology

This executive summary is developed using a structured secondary research approach centered on verified public health, clinical, regulatory, and demographic sources. The methodology incorporates evidence from international health agencies, national fertility registries, peer-reviewed reproductive medicine literature, clinical society guidance, government policy documents, insurance and reimbursement information, and publicly available regulatory frameworks governing assisted reproductive technology, gamete donation, embryo storage, genetic testing, and fertility preservation. Regional and country insights are synthesized by examining healthcare infrastructure, fertility treatment access, reimbursement policies, demographic trends, legal permissibility, clinical capacity, and adoption of reproductive technologies. The analysis avoids market sizing, market share estimation, and forecasting, focusing instead on data-backed qualitative interpretation of infertility treatment dynamics. Findings are cross-checked across multiple credible sources to reduce bias and ensure consistency, while recognizing that ART regulation, funding, and reporting practices differ substantially by jurisdiction.

Conclusion

Infertility treatment is becoming a more integrated, technology-enabled, and policy-sensitive area of healthcare as the global burden of infertility intersects with demographic change, delayed parenthood, and expanding reproductive choice. Advances in IVF, cryopreservation, genetic testing, fertility preservation, and digital health are improving care pathways, while artificial intelligence has the potential to enhance consistency and efficiency when implemented responsibly. Regional and national differences in reimbursement, regulation, culture, and clinical infrastructure continue to shape access and patient decision-making. The most resilient stakeholders will be those that combine clinical excellence with ethical governance, affordability initiatives, transparent communication, and patient-centered care. As demand for reproductive healthcare grows, the future of infertility treatment will be defined not only by technological progress but also by equitable access, regulatory trust, and measurable improvements in patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Infertility Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Medication Therapy
    • 7.2.1. Ovulation Induction
    • 7.2.2. Luteal Phase Support
  • 7.3. Assisted Reproductive Technology
    • 7.3.1. In Vitro Fertilization
    • 7.3.2. Intracytoplasmic Sperm Injection
  • 7.4. Artificial Insemination
    • 7.4.1. Intrauterine Insemination
    • 7.4.2. Intracervical Insemination
  • 7.5. Surgical Treatment
    • 7.5.1. Laparoscopic Procedures
    • 7.5.2. Hysteroscopic Procedures

8. Infertility Treatment Market, by Product Type

  • 8.1. Introduction
  • 8.2. Equipment
    • 8.2.1. Cryosystems
    • 8.2.2. Imaging Systems
    • 8.2.3. Incubators
    • 8.2.4. Laser Systems
    • 8.2.5. Micromanipulator Systems
    • 8.2.6. Ovum Aspiration Pumps
    • 8.2.7. Sperm Analyzer Systems
    • 8.2.8. Sperm Separation Devices
    • 8.2.9. Embryo Monitoring/Witnessing
    • 8.2.10. Andrology Lab Equipment
  • 8.3. Media
    • 8.3.1. Cryopreservation Media
    • 8.3.2. Culture Media
  • 8.4. Accessories & Consumables

9. Infertility Treatment Market, by Diagnosis

  • 9.1. Introduction
  • 9.2. Female Infertility
    • 9.2.1. Hysterosalpingography (HSG)
    • 9.2.2. Ovulation Testing
  • 9.3. Male Infertility
    • 9.3.1. Blood Tests
    • 9.3.2. Semen Analysis
    • 9.3.3. Testicular Biopsy

10. Infertility Treatment Market, by Infertility Type

  • 10.1. Introduction
  • 10.2. Primary Infertility
  • 10.3. Secondary Infertility

11. Infertility Treatment Market, by End User

  • 11.1. Introduction
  • 11.2. Fertility Clinics
  • 11.3. Hospitals
  • 11.4. Ambulatory Surgical Centers
  • 11.5. Cryobanks

12. Infertility Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Europe
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Infertility Treatment Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Infertility Treatment Market, by Country

  • 14.1. United States
  • 14.2. China
  • 14.3. Germany
  • 14.4. Japan
  • 14.5. Canada
  • 14.6. India
  • 14.7. Brazil
  • 14.8. United Kingdom
  • 14.9. Mexico
  • 14.10. France
  • 14.11. Australia
  • 14.12. Italy
  • 14.13. South Korea
  • 14.14. Russia
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Merck KGaA
  • 16.2. Ferring International Center S.A.
  • 16.3. IVIRMA
  • 16.4. CooperSurgical, Inc.
  • 16.5. Vitrolife Sweden AB
  • 16.6. FUJIFILM Biosciences
  • 16.7. Monash IVF
  • 16.8. Genea Group
  • 16.9. Cryoport Systems, LLC.
  • 16.10. Bayer AG
  • 16.11. Abbott Laboratories
  • 16.12. Hamilton Thorne Ltd.
  • 16.13. TMRW Life Sciences, Inc.
  • 16.14. Embryolab
  • 16.15. Cook Medical LLC
  • 16.16. AbbVie Inc.
  • 16.17. Esco Micro Pte. Ltd.
  • 16.18. Fairhaven Health, Inc.
  • 16.19. NOW-fertility SA
  • 16.20. ReproTech LLC
  • 16.21. Seegene, Inc.
  • 16.22. Thermo Fisher Scientific, Inc.
  • 16.23. Xytex Corporation
  • 16.24. Zuellig Pharma Group
  • 16.25. Zydus Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFERTILITY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INFERTILITY TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INFERTILITY TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INFERTILITY TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INFERTILITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL INFERTILITY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL INFERTILITY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MEDICATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MEDICATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OVULATION INDUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OVULATION INDUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OVULATION INDUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LUTEAL PHASE SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUTEAL PHASE SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LUTEAL PHASE SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN VITRO FERTILIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN VITRO FERTILIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN VITRO FERTILIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRACYTOPLASMIC SPERM INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRACYTOPLASMIC SPERM INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRACYTOPLASMIC SPERM INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INSEMINATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INSEMINATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INSEMINATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAUTERINE INSEMINATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRAUTERINE INSEMINATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAUTERINE INSEMINATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRACERVICAL INSEMINATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRACERVICAL INSEMINATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRACERVICAL INSEMINATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LAPAROSCOPIC PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LAPAROSCOPIC PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LAPAROSCOPIC PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYSTEROSCOPIC PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HYSTEROSCOPIC PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYSTEROSCOPIC PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CRYOSYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRYOSYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRYOSYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INCUBATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INCUBATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INCUBATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LASER SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LASER SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LASER SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MICROMANIPULATOR SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MICROMANIPULATOR SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MICROMANIPULATOR SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OVUM ASPIRATION PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OVUM ASPIRATION PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OVUM ASPIRATION PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPERM ANALYZER SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPERM ANALYZER SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPERM ANALYZER SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SPERM SEPARATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SPERM SEPARATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SPERM SEPARATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EMBRYO MONITORING/WITNESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EMBRYO MONITORING/WITNESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EMBRYO MONITORING/WITNESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANDROLOGY LAB EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANDROLOGY LAB EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANDROLOGY LAB EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MEDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MEDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRYOPRESERVATION MEDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CRYOPRESERVATION MEDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRYOPRESERVATION MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CULTURE MEDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CULTURE MEDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACCESSORIES & CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACCESSORIES & CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACCESSORIES & CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL FEMALE INFERTILITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL FEMALE INFERTILITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL FEMALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HYSTEROSALPINGOGRAPHY (HSG) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HYSTEROSALPINGOGRAPHY (HSG) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HYSTEROSALPINGOGRAPHY (HSG) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OVULATION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OVULATION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OVULATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MALE INFERTILITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SEMEN ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SEMEN ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SEMEN ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TESTICULAR BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TESTICULAR BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TESTICULAR BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PRIMARY INFERTILITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PRIMARY INFERTILITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PRIMARY INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SECONDARY INFERTILITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SECONDARY INFERTILITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SECONDARY INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL FERTILITY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL FERTILITY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL FERTILITY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRYOBANKS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CRYOBANKS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CRYOBANKS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. NATO INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. NATO INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 219. NATO INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 220. NATO INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 222. NATO INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 223. NATO INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. G7 INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. G7 INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. G7 INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 233. G7 INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 234. G7 INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 236. G7 INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 237. G7 INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. GCC INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. GCC INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. GCC INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 287. GCC INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. GCC INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 289. GCC INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 290. GCC INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. GCC INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 292. GCC INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 293. GCC INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 295. GCC INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 296. GCC INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. GCC INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. GERMANY INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 330. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY INFERTILITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 341. JAPAN INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. JAPAN INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. JAPAN INFERTILITY TREATMENT MARKET SIZE, BY MEDICATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 344. JAPAN INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 345. JAPAN INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2032 (USD MILLION)
  • TABLE 346. JAPAN INFERTILITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 347. JAPAN INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 348. JAPAN INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 349. JAPAN INFERTILITY TREATMENT MARKET SIZE, BY MEDIA, 2018-2032 (USD MILLION)
  • TABLE 350. JAPAN INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 351. JAPAN INFERTILITY TREATMENT MARKET SIZE, B